Thanks to "Ridge1" posting on another (cancer related) stock on that respective HC message board today, I can quote just some short parts of his quite long post hereafter. I hope that "Ridge1" will not mind!
Partial quotes:
From USA's ENDPOINT NEWS today Albert Bourla has some plans for Pfizer's huge Covid cash haul. ............and what a fresh flow of $54 billion-plus from the pandemic franchise this year can do for the company. ..........Aamir Malik told analysts: "We have said repeatedly that we are most interested in compounds that have the potential to be real breakthroughs. ...."
ONCOLOGY, VACCINES, RARE DISEASES and INTERNAL MEDICINE are among the core focuses in R&D, and Malik said they'll continue to be active "where we have the scientific chops to make good scientific choices and add real value."
End of partial quotes
My musings on this: Acadia/NEU are very WELL POSITIONED to be on PFIZER's RADAR ! I do not know what percentage of that US$ 54 billion would need to be touched to buy-out both companies IF that would be of real interest to Pfizer's efforts in the RARE DISEASES field...
Comments welcome as usual.
wasa
NEU Price at posting:
$4.38 Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)